DAIICHI SANKYO ILAÇ TICARET Ltd. Sti., the Turkish subsidiary of Japan's second-largest pharmaceutical company, has obtained 20 members of the cardio-metabolism sales force at Merck ILAÇ Ltd, a subsidiary of Merck Serono in Turkey. The agreement also includes the transfer of marketing-authorization for Concor, an anti-hypertensive medication, and Glucophage, a diabetes agent.
The details can be read here.
No comments:
Post a Comment